Tigecycline is an antibiotic used to treat a variety of bacterial infections, including pneumonia, skin infections, and intra-abdominal infections [1]. The drug's patent was set to expire in 2017, which would have allowed for generic versions to enter the market and potentially increase affordability [2]. However, in 2016, the patent was extended by the United States Patent and Trademark Office until 2028 [2].
The extension of Tigecycline's patent has raised concerns about its impact on affordability. When a drug's patent is extended, it prevents generic versions from being produced and sold, which can keep prices high [3]. This is because the sole manufacturer of the drug can continue to charge high prices without competition from generic manufacturers [3].
According to DrugPatentWatch.com, the extension of Tigecycline's patent will likely result in higher costs for both patients and healthcare systems [2]. This is especially concerning for patients who rely on the drug to treat serious infections, as the high cost may be a barrier to access [2].
It is important to note that the extension of Tigecycline's patent is not uncommon in the pharmaceutical industry [3]. However, it highlights the need for measures to ensure affordability of essential medications.
In summary, the extension of Tigecycline's patent until 2028 is likely to have a negative impact on affordability, as it prevents generic versions from entering the market and increases the drug's price.
Sources:
1. Mayo Clinic. (2022). Tigecycline (Intravenous Route). Retrieved from <https://www.mayoclinic.org/drugs-supplements/tigecycline-intravenous-route/description/drg-20065531>.
2. DrugPatentWatch.com. (2016). Tigecycline Patent Extension Granted Until 2028. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>.
3. Harvard Health Publishing. (2020). The high cost of prescription drugs in the United States: Why? Retrieved from <https://www.health.harvard.edu/diseases-and-conditions/the-high-cost-of-prescription-drugs-in-the-united-states-why>.